Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving fixed or stabilized – nonliving microorganism,...
Reexamination Certificate
2005-11-01
2005-11-01
Canella, Karen A. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving fixed or stabilized, nonliving microorganism,...
C435S371000, C436S064000
Reexamination Certificate
active
06960449
ABSTRACT:
The present invention relates to the identification and characterization of classes and subclasses of circulating cancer cells, including microtumors from body fluid samples using molecular, cytological, and morphological analyses, and methods for staging patients and measuring the efficacy of medical treatments.
REFERENCES:
patent: 5633945 (1997-05-01), Kamentsky
patent: 5674694 (1997-10-01), Ross
patent: 5962237 (1999-10-01), Ts'o et al.
patent: 6025128 (2000-02-01), Veltri et al.
patent: 6169816 (2001-01-01), Ravkin
patent: 6197523 (2001-03-01), Rimm et al.
LaVia et al (Principles of Pathobiology, 1975, p. 213).
Maggi et al (Cangro, 1963, vol. 16, pp. 169-188).
Pavone et al (Clinical Ostetrica E Ginecologica, 1963, vol. 65, pp. 475-480).
Orkin et al (“Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995).
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101).
Leverrier et al, Current Biology, 2001, vol. 11, pp. 195-199.
Ordonez, American Journal of Surgical Pathology, 1998, vol. 22, pp. 1215-1221.
Wang, Z.P. et al., “Detection incidence of circulating cancer cells from prostate cancer patients' blood,” Abstract No. 4708, from theAmerican Association of Cancer Research(AACR)Annual Meeting, Philadelphia, Pennsylvania (Apr. 10-14, 1999).
Wang, Z. -P. et al., “Identification and Characterization of Circulating Prostate Carcinoma Cells,”Cancer 88:2787-2795, American Cancer Society (Jun. 15, 2000).
Wang, Z.P. et al., “Indications of living circulating prostatic cancer cells in the prostatic cancer patients' blood,” fromInternational Symposium on Biology of Prostate Growth, National Institutes of Health, Bethesda, Maryland (Mar. 15-18, 1998).
Wang, Z. -P. et al., “Intravascular growth may occur in the formation of a metastatic tumor,”Conference on New Research Approaches in the Prevention and Cure of Prostate Cancer, Indian Wells, California, American Association for Cancer Research (Dec. 2-6, 1998).
Polascik, T.J. et al., “Influence of Sextant Prostate Needle Biopsy or Surgery on the Detection and Harvest of Intact Circulating Prostate Cancer Cells,”J. Urology 162:749-752, American Urological Association, Inc. (Sep. 1999).
Ts'o, P.O.P., “Biomarkers Expression and Characterization of Prostate Cancer Circulating Cells,” fromScientific Poster Reproductions: Sixth Annual Scientific Retreat, Lake Tahoe, Nevada, Oct. 14-17, 1999, Association for the Cure of Cancer of the Prostate, Santa Monica, California.
Ts'o, P.O.P. et al., “Detection and Characterization of Circulating Prostate Cancer Cells in the Blood of Patients with Prostate Cancer,” fromAnnual Meeting for the Society of Chinese Bioscientists in America, Toronto (Jul. 1997).
Chen, K.Y. et al., “Detection of Circulating Cancer Cells from Prostate Cancer Patients' Blood,”The First China Taiwan Cancer Conference, Haerbing, People's Republic of China (Jan. 8-12, 1999).
Polascik, T.J. et al., “Harvest of Intact Prostate Cancer Cells from Blood: Further Characterization of a New Assay,”J. Urology159:Supplement (May 31, 1998), from theAnnual Meeting of the American Urological Association, San Diego, California, May 30-Jun. 4, 1998.
Coleman, A.W., et al., “Mithramycin- and 4′-6-Diamidino-2-Phenylindole (DAPI)-DNA Staining for Fluorescence Microspectrophotometric Measurement of DNA in Nuclei, Plastids, and Virus Particles,”J. Histochem.&Cytochem. 29: 959-968 (Aug. 1981).
Cote, R.J., et al., “Association of p27Kip1Levels with Recurrence and Survival in Patients with Stage C Prostate Carcinoma,”J. Nat. Cancer Inst. 90:916-920 (Jun. 1998).
Cordon-Cardo, C., et al., “Distinct Altered Patterns of p27KIP1Gene Expression in Benign Prostatic Hyperplasia and Prostastic Carcinoma,”J. Nat. Cancer Inst. 90:1284-1291 (Sep. 1998).
El-Habashi, A.H., et al.,“DNA Ploidy and Proliferating Cell Nuclear Antigen Image Analysis of Peritoneal and Pleural Effusions,”Acta. Cytol. 41:636-648 (May-Jun. 1997).
Fernandes, B.J., et al., “DNA Content and Estrogen Receptors in Primary Carcinoma of the Breast,”Can. J. Surg. 34:349-355 (Aug. 1991).
Fidler, I.J., et al., “Critical Factors in the Biology of Human Cancer Metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture,”Cancer Res. 50:6130-6138 (Oct. 1990).
Galand, P. and Degraef, C., “Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for making S phase cells in paraffin sections from animal and human tissues,”Cell Tissue Kinet. 22:383-392 (Sep. 1989).
Gerdes, J., et al., “Production of a Mouse Monoclonal Antibody Reactive with a Human Nuclear Antigen Associated with Cell Proliferation,”Int. J. Cancer. 31:13-20 (Jan. 1983).
Hall, P.A., et al.,“Proliferating Cell Nuclear Antigen (PCNA) Immunolocalization in Paraffin Sections: An Index of Cell Proliferation with Evidence of Deregulated Expression in Some Neoplasms,”J. Pathol. 162:285-294 (Dec. 1990).
Herbeuval, R., et al., “Diagnosis of Unusual Blood Cells by Immunofluorescence,”Acta. Cytol. 9:73-82 (Jan.-Feb. 1965).
Kallakury, B.V.S., et al., “The Prognostic Significance of p34cdc2and Cyclin D1 Protein Expression in Prostate Adenocarcinoma,”Cancer 80:753-763 (Aug. 1997).
Key, G., et al.,“New Ki-67-Equivalent Murine Monoclonal Antibodies (MIB 1-3) Generated Aganist Bacterially Expressed Parts of the Ki-67 cDNA Containing Three 62 Base Pair Repetitive Elements Encoding for the Ki-67 Epitope,”Lab Invest. 68:629-636 (Jun. 1993).
Kirkegaard, L.J. et al., “Image Cytometric Measurement of Nuclear Proliferation Markers (MIB-1, PCNA) in Astrocytomas,”Am. J. Clin. 109:69-74 (Jan. 1998).
Lee, A.K.C., et al., “DNA Ploidy, Proliferation, and Neu-oncogene Protein Overexpression in Breast Carcinoma,”Mod. Pathol. 5:61-67 (Jan. 1992).
Leong, A.S.-Y. and Milios, J., “Is Immunolocalisation of Proliferating Cell Nuclear Antigen (PCNA) in Parrafin Sections a Valid Index of Cell Proliferation?”Appl. Immunohistochem. 1:127-135 (1993).
Makris, A., et al., “Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response,”Breast Cancer Res. Treat. 48:11-20 (Mar. 1998).
Nagy, K.P., “A Study of Normal, Atypical and Neoplastic Cells in the White Cell Concentration of the Peripheral Blood,”Acat Cytol. 9:61-67 (Jan.-Feb. 1965).
Sasano, H., et al., “Immunolocalization of Cyclins D and E and Cyclin Dependent Kinase (cdk) 2 and 4 in Human Breast Carcinoma,”Anticancer Res. 17:3685-3690 (Sep.-Oct. 1997).
Scambia, G., et al., “Multiple Tumour Marker Assays in Advanced Cervical Cancer: Relationship to Chemotherapy Response and Clinical Outcome,”Eur. J. Cancer 32A:259-263 (Feb. 1996).
Siitonen, S.M., et al., “Proliferating Cell Nuclear Antigen Immunohistochemistry Using Monoclonal Antibody 19A2 and a New Antigen Retrieval Technique Has Prognostic Impact in Archival Paraffin-Embedded Node-Negative Breast Cancer,”Am. J. Pathol. 142:1081-1089 (Apr. 1993).
Tsihlias, J., et al., “Loss of Cyclin-dependent Kinase Inhibitor p27Kip1Is a Novel Prognostic Factor in Localized Human Prostate Adenocarcinoma,”Cancer Res. 58:542-548 (Feb. 1998).
Ts'o P.O.P., et al., “Detection of Intact Prostate Cancer Cells in the Blood of Men with Prostate Cancer,”Urology 49:811-885 (Jun. 1997).
Vielh, P., “Ki67 Index and S-Phase Fraction in Human Breast Carcinomas,”Am. J. Clin. Pathol. 94:681-686 (Dec. 1990).
Wingren, S., et al., “Flow cytometric analysis of S-phase fraction in brest carcinomas using gating on cells containing cytokeratin,”Br. J. Cancer 69:546-549 (Mar. 1994)
T'so Paul O. P.
Wang Zheng-Pin
Canella Karen A.
Cell Works Diagnostics, Inc.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Class characterization of circulating cancer cells isolated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Class characterization of circulating cancer cells isolated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Class characterization of circulating cancer cells isolated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3513431